US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

Parabilis Medicines, Inc. - Common Stock (NQ:PBLS)

22.75 -2.43 (-9.65%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Parabilis Medicines, Inc. - Common Stock

News headline image
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
From Parabilis Medicines, Inc.
Via GlobeNewswire
News headline image
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Parabilis Medicines, Inc.
Via GlobeNewswire
News headline image
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Parabilis Medicines, Inc.
Via GlobeNewswire
News headline image
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Parabilis Medicines, Inc.
Via GlobeNewswire
News headline image
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
From Parabilis Medicines, Inc.
Via GlobeNewswire